Full text is available at the source.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are noted for their role in managing obesity and type 2 diabetes mellitus (T2DM).
- Randomized clinical trials show substantial weight loss and metabolic benefits associated with GLP-1RAs.
- Real-world evidence is necessary to better understand outcomes related to weight and health in everyday clinical settings.
- The study highlights the importance of characterizing safety and prescribing patterns for GLP-1RAs during routine treatment.
Simplified